{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,15]],"date-time":"2026-06-15T12:57:40Z","timestamp":1781528260417,"version":"3.54.1"},"reference-count":68,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,7,1]],"date-time":"2026-07-01T00:00:00Z","timestamp":1782864000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,7,1]],"date-time":"2026-07-01T00:00:00Z","timestamp":1782864000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,5,28]],"date-time":"2026-05-28T00:00:00Z","timestamp":1779926400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/100019914","name":"Flatiron Health","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100019914","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100002429","name":"Amgen Inc","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100002429","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100019139","name":"Life Sciences, University of California, Los Angeles","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100019139","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","lungcancerjournal.info","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Lung Cancer"],"published-print":{"date-parts":[[2026,7]]},"DOI":"10.1016\/j.lungcan.2026.109471","type":"journal-article","created":{"date-parts":[[2026,5,25]],"date-time":"2026-05-25T16:08:03Z","timestamp":1779725283000},"page":"109471","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"special_numbering":"C","title":["First-line treatment patterns and real-world outcomes in patients with advanced KRAS-mutated non-small cell lung cancer with high unmet need"],"prefix":"10.1016","volume":"217","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-5793-3539","authenticated-orcid":false,"given":"Fabrice","family":"Barlesi","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ferdinandos","family":"Skoulidis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Benjamin","family":"Solomon","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8993-8959","authenticated-orcid":false,"given":"Joowon","family":"Lee","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rami","family":"Jassim","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ravi","family":"Gupta","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marco","family":"Mesa-Frias","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Enriqueta","family":"Felip","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.lungcan.2026.109471_b0005","unstructured":"Lung. International Agency for Research on Cancer Global Cancer Observatory: Cancer Today. World Health Organization. https:\/\/gco.iarc.who.int\/media\/globocan\/factsheets\/cancers\/15-trachea-bronchus-and-lung-fact-sheet.pdf., 2022. (Accessed September 22 2025)."},{"issue":"1","key":"10.1016\/j.lungcan.2026.109471_b0010","doi-asserted-by":"crossref","DOI":"10.1002\/cncr.35476","article-title":"Survival trends among patients with metastatic non-small cell lung cancer before and after the approval of immunotherapy in the United States: a surveillance, epidemiology, and end results database-based study","volume":"131","author":"Wang","year":"2025","journal-title":"Cancer"},{"issue":"4","key":"10.1016\/j.lungcan.2026.109471_b0015","doi-asserted-by":"crossref","first-page":"530","DOI":"10.1002\/cncr.35094","article-title":"Association between treatment and improvements in overall survival of patients with advanced\/metastatic non-small cell lung cancer since 2011: a study in the United States, Canada, and Germany Using Retrospective Real-World Databases","volume":"130","author":"Griesinger","year":"2024","journal-title":"Cancer"},{"issue":"2","key":"10.1016\/j.lungcan.2026.109471_b0020","first-page":"117","article-title":"First-line immunotherapy for advanced non-small cell lung cancer: current progress and future prospects","volume":"21","author":"Wang","year":"2023","journal-title":"Cancer Biol. Med."},{"issue":"1","key":"10.1016\/j.lungcan.2026.109471_b0025","doi-asserted-by":"crossref","first-page":"24","DOI":"10.1186\/s40364-024-00566-0","article-title":"Oncogenic alterations in advanced NSCLC: a molecular super-highway","volume":"12","author":"Friedlaender","year":"2024","journal-title":"Biomark Res"},{"issue":"4","key":"10.1016\/j.lungcan.2026.109471_b0030","doi-asserted-by":"crossref","first-page":"217","DOI":"10.5306\/wjco.v12.i4.217","article-title":"Oncogenic driver mutations in non-small cell lung cancer: past, present and future","volume":"12","author":"Chevallier","year":"2021","journal-title":"World J Clin Oncol"},{"issue":"11","key":"10.1016\/j.lungcan.2026.109471_b0035","doi-asserted-by":"crossref","DOI":"10.3390\/biom13111587","article-title":"A nexus between genetic and non-genetic mechanisms guides KRAS inhibitor resistance in lung cancer","volume":"13","author":"Kulkarni","year":"2023","journal-title":"Biomolecules"},{"issue":"6","key":"10.1016\/j.lungcan.2026.109471_b0040","doi-asserted-by":"crossref","DOI":"10.3390\/curroncol32060365","article-title":"KRAS mutations as predictive biomarkers for first-line immune checkpoint inhibitor monotherapy in advanced NSCLC: a systematic review and meta-analysis","volume":"32","author":"Markovic","year":"2025","journal-title":"Curr. Oncol."},{"issue":"16","key":"10.1016\/j.lungcan.2026.109471_b0045","doi-asserted-by":"crossref","first-page":"5061","DOI":"10.1158\/1078-0432.CCR-18-4275","article-title":"Tumor Characteristics associated with benefit from pembrolizumab in advanced non-small cell lung cancer","volume":"25","author":"Hu-Lieskovan","year":"2019","journal-title":"Clin. Cancer Res."},{"issue":"1","key":"10.1016\/j.lungcan.2026.109471_b0050","doi-asserted-by":"crossref","DOI":"10.1080\/2162402X.2020.1746112","article-title":"Identifying optimal first-line interventions for advanced non-small cell lung carcinoma according to PD-L1 expression: a systematic review and network meta-analysis","volume":"9","author":"Liu","year":"2020","journal-title":"Oncoimmunology"},{"issue":"1","key":"10.1016\/j.lungcan.2026.109471_b0055","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1093\/jnci\/djac205","article-title":"Predictors of survival to immunotherapy and chemoimmunotherapy in non-small cell lung cancer: a meta-analysis","volume":"115","author":"Di Federico","year":"2023","journal-title":"J. Natl Cancer Inst."},{"issue":"3","key":"10.1016\/j.lungcan.2026.109471_b0060","doi-asserted-by":"crossref","first-page":"768","DOI":"10.20892\/j.issn.2095-3941.2020.0121","article-title":"Molecular heterogeneity of anti-PD-1\/PD-L1 immunotherapy efficacy is correlated with tumor immune microenvironment in East Asian patients with non-small cell lung cancer","volume":"17","author":"Jin","year":"2020","journal-title":"Cancer Biol. Med."},{"key":"10.1016\/j.lungcan.2026.109471_b0065","article-title":"Efficacy of PD-1 or PD-L1 inhibitors and PD-L1 expression status in cancer: meta-analysis","volume":"362","author":"Shen","year":"2018","journal-title":"BMJ"},{"issue":"9","key":"10.1016\/j.lungcan.2026.109471_b0070","doi-asserted-by":"crossref","first-page":"3845","DOI":"10.7150\/ijbs.70958","article-title":"VEGF\/VEGFR-targeted therapy and immunotherapy in non-small cell lung cancer: targeting the tumor microenvironment","volume":"18","author":"Zhao","year":"2022","journal-title":"Int. J. Biol. Sci."},{"issue":"4","key":"10.1016\/j.lungcan.2026.109471_b0075","doi-asserted-by":"crossref","first-page":"315","DOI":"10.1016\/j.cllc.2018.02.006","article-title":"Clinical and molecular predictors of PD-L1 expression in non-small-cell lung cancer: systematic review and meta-analysis","volume":"19","author":"Petrelli","year":"2018","journal-title":"Clin. Lung Cancer"},{"issue":"9","key":"10.1016\/j.lungcan.2026.109471_b0080","doi-asserted-by":"crossref","first-page":"2371","DOI":"10.1093\/annonc\/mdt205","article-title":"Mutation incidence and coincidence in non small-cell lung cancer: meta-analyses by ethnicity and histology (mutMap)","volume":"24","author":"Dearden","year":"2013","journal-title":"Ann. Oncol."},{"issue":"11","key":"10.1016\/j.lungcan.2026.109471_b0085","doi-asserted-by":"crossref","first-page":"1992","DOI":"10.1200\/JCO.22.01989","article-title":"Pembrolizumab plus pemetrexed and platinum in nonsquamous non-small-cell lung cancer: 5-year outcomes from the phase 3 KEYNOTE-189 study","volume":"41","author":"Garassino","year":"2023","journal-title":"J. Clin. Oncol."},{"issue":"6","key":"10.1016\/j.lungcan.2026.109471_b0090","doi-asserted-by":"crossref","first-page":"1200","DOI":"10.1200\/JCO.22.01503","article-title":"Five-year survival outcomes with nivolumab plus ipilimumab versus chemotherapy as first-line treatment for metastatic non-small-cell lung cancer in CheckMate 227","volume":"41","author":"Brahmer","year":"2023","journal-title":"J. Clin. Oncol."},{"issue":"3","key":"10.1016\/j.lungcan.2026.109471_b0095","article-title":"Additional impact of genetic ancestry over race\/ethnicity to prevalence of KRAS mutations and allele-specific subtypes in non-small cell lung cancer","volume":"5","author":"Wang","year":"2024","journal-title":"HGG Adv"},{"key":"10.1016\/j.lungcan.2026.109471_b0100","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.lungcan.2022.03.015","article-title":"van der Wekken, Prevalence of KRAS p.(G12C) in stage IV NSCLC patients in the Netherlands; a nation-wide retrospective cohort study","volume":"167","author":"Garcia","year":"2022","journal-title":"Lung Cancer"},{"issue":"18","key":"10.1016\/j.lungcan.2026.109471_b0105","doi-asserted-by":"crossref","first-page":"5731","DOI":"10.1158\/1078-0432.CCR-08-0646","article-title":"Frequency and distinctive spectrum of KRAS mutations in never smokers with lung adenocarcinoma","volume":"14","author":"Riely","year":"2008","journal-title":"Clin. Cancer Res."},{"issue":"4","key":"10.1016\/j.lungcan.2026.109471_b0110","doi-asserted-by":"crossref","DOI":"10.1136\/bmjopen-2013-002560","article-title":"The frequency of EGFR and KRAS mutations in non-small cell lung cancer (NSCLC): routine screening data for central Europe from a cohort study","volume":"3","author":"Boch","year":"2013","journal-title":"BMJ Open"},{"issue":"5","key":"10.1016\/j.lungcan.2026.109471_b0115","doi-asserted-by":"crossref","first-page":"195","DOI":"10.1016\/j.cancergen.2016.03.001","article-title":"The potential utility of re-mining results of somatic mutation testing: KRAS status in lung adenocarcinoma","volume":"209","author":"Biernacka","year":"2016","journal-title":"Cancer Genet."},{"issue":"12","key":"10.1016\/j.lungcan.2026.109471_b0120","doi-asserted-by":"crossref","first-page":"2577","DOI":"10.1158\/1535-7163.MCT-21-0201","article-title":"Characterization of KRAS Mutation Subtypes in Non-small Cell Lung Cancer","volume":"20","author":"Judd","year":"2021","journal-title":"Mol. Cancer Ther."},{"key":"10.1016\/j.lungcan.2026.109471_b0125","doi-asserted-by":"crossref","DOI":"10.1016\/j.lungcan.2023.107293","article-title":"KRAS G12C in advanced NSCLC: Prevalence, co-mutations, and testing","volume":"184","author":"Lim","year":"2023","journal-title":"Lung Cancer"},{"key":"10.1016\/j.lungcan.2026.109471_b0130","doi-asserted-by":"crossref","first-page":"95","DOI":"10.1016\/j.canlet.2019.10.027","article-title":"The superior efficacy of anti-PD-1\/PD-L1 immunotherapy in KRAS-mutant non-small cell lung cancer that correlates with an inflammatory phenotype and increased immunogenicity","volume":"470","author":"Liu","year":"2020","journal-title":"Cancer Lett."},{"key":"10.1016\/j.lungcan.2026.109471_b0135","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejca.2024.113985","article-title":"Clinicopathologic features, concurrent genomic alterations, and clinical outcomes of patients with KRAS G12D mutations in resected lung adenocarcinoma","volume":"202","author":"Cao","year":"2024","journal-title":"Eur. J. Cancer"},{"key":"10.1016\/j.lungcan.2026.109471_b0140","doi-asserted-by":"crossref","DOI":"10.1177\/17588359231225036","article-title":"Efficacy of immunotherapy in patients with oncogene-driven non-small-cell lung cancer: a systematic review and meta-analysis","volume":"16","author":"Chen","year":"2024","journal-title":"Ther Adv Med Oncol"},{"key":"10.1016\/j.lungcan.2026.109471_b0145","article-title":"Efficacy of immunotherapy in KRAS-mutant advanced NSCLC: a real-world study in a Chinese population","volume":"12","author":"Peng","year":"2022","journal-title":"Front. Oncol."},{"issue":"3","key":"10.1016\/j.lungcan.2026.109471_b0150","doi-asserted-by":"crossref","first-page":"228","DOI":"10.1016\/j.cllc.2023.01.009","article-title":"A multicenter retrospective chart review of clinical outcomes among patients with KRAS G12C mutant non-small cell lung cancer","volume":"24","author":"Iams","year":"2023","journal-title":"Clin. Lung Cancer"},{"key":"10.1016\/j.lungcan.2026.109471_b0155","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1016\/j.lungcan.2021.04.007","article-title":"Real-world outcomes of immunotherapy-based regimens in first-line advanced non-small cell lung cancer","volume":"156","author":"Waterhouse","year":"2021","journal-title":"Lung Cancer"},{"key":"10.1016\/j.lungcan.2026.109471_b0160","unstructured":"Ma X, Long L, Moon S, Adamson BJS, B. SS., Comparison of population characteristics in real-world clinical oncology databases in the US: Flatiron Health, SEER, and NPCR, medRxiv (2023)."},{"issue":"6","key":"10.1016\/j.lungcan.2026.109471_b0165","doi-asserted-by":"crossref","first-page":"1281","DOI":"10.1111\/1475-6773.13669","article-title":"Validation analysis of a composite real-world mortality endpoint for patients with cancer in the United States","volume":"56","author":"Zhang","year":"2021","journal-title":"Health Serv. Res."},{"key":"10.1016\/j.lungcan.2026.109471_b0170","unstructured":"Birnbaum B, Nussbaum N, Seidl-Rathkopf K, et al, Model-assisted cohort selection with bias analysis for generating large-scale cohorts from the EHR for oncology research, arXiv (2020)."},{"key":"10.1016\/j.lungcan.2026.109471_b0175","doi-asserted-by":"crossref","DOI":"10.3389\/fphar.2023.1180962","article-title":"Approach to machine learning for extraction of real-world data variables from electronic health records","volume":"14","author":"Adamson","year":"2023","journal-title":"Front. Pharmacol."},{"issue":"13","key":"10.1016\/j.lungcan.2026.109471_b0180","doi-asserted-by":"crossref","DOI":"10.3390\/cancers14133063","article-title":"Considerations for the use of machine learning extracted real-world data to support evidence generation: a research-centric evaluation framework","volume":"14","author":"Estevez","year":"2022","journal-title":"Cancers (Basel)"},{"key":"10.1016\/j.lungcan.2026.109471_b0185","article-title":"Raising the bar for real-world data in oncology: approaches to quality across multiple dimensions","volume":"8","author":"Castellanos","year":"2024","journal-title":"JCO Clin Cancer Inform"},{"issue":"6","key":"10.1016\/j.lungcan.2026.109471_b0190","doi-asserted-by":"crossref","DOI":"10.3390\/cancers15061853","article-title":"Replication of real-world evidence in oncology using electronic health record data extracted by machine learning","volume":"15","author":"Benedum","year":"2023","journal-title":"Cancers (Basel)"},{"issue":"22","key":"10.1016\/j.lungcan.2026.109471_b0195","doi-asserted-by":"crossref","first-page":"2078","DOI":"10.1056\/NEJMoa1801005","article-title":"Pembrolizumab plus chemotherapy in metastatic non-small-cell lung cancer","volume":"378","author":"Gandhi","year":"2018","journal-title":"N. Engl. J. Med."},{"issue":"6","key":"10.1016\/j.lungcan.2026.109471_b0200","doi-asserted-by":"crossref","DOI":"10.1016\/j.esmoop.2023.102065","article-title":"Nivolumab plus chemotherapy in first-line metastatic non-small-cell lung cancer: results of the phase III CheckMate 227 Part 2 trial","volume":"8","author":"Borghaei","year":"2023","journal-title":"ESMO Open"},{"issue":"1","key":"10.1016\/j.lungcan.2026.109471_b0205","doi-asserted-by":"crossref","first-page":"76","DOI":"10.1016\/j.jtho.2024.09.1381","article-title":"Durvalumab with or without tremelimumab in combination with chemotherapy in first-line metastatic NSCLC: five-year overall survival outcomes from the phase 3 POSEIDON trial","volume":"20","author":"Peters","year":"2025","journal-title":"J. Thorac. Oncol."},{"key":"10.1016\/j.lungcan.2026.109471_b0210","doi-asserted-by":"crossref","unstructured":"D.J. Cantor, H. Nimeiri, L. Horn, M. West, R. Ben-Shachar, I. Huerga, J.D. Patel, C. Aggarwal, Outcomes Following First-Line Immune Checkpoint Inhibitors With or Without Chemotherapy Stratified by KRAS Mutational Status-A Real-World Analysis in Patients With Advanced NSCLC, Clin Lung Cancer 26(6) (2025) 503-510 e4.","DOI":"10.1016\/j.cllc.2025.05.007"},{"issue":"11","key":"10.1016\/j.lungcan.2026.109471_b0215","doi-asserted-by":"crossref","first-page":"895","DOI":"10.1111\/1759-7714.15244","article-title":"Association of PD-L1 expression with driver gene mutations and clinicopathological characteristics in non-small cell lung cancer: a real-world study of 10 441 patients","volume":"15","author":"Ruiz","year":"2024","journal-title":"Thorac Cancer"},{"issue":"7","key":"10.1016\/j.lungcan.2026.109471_b0220","doi-asserted-by":"crossref","first-page":"7684","DOI":"10.18632\/oncotarget.23969","article-title":"Association between PD-L1 expression and driver gene status in non-small-cell lung cancer: a meta-analysis","volume":"9","author":"Lan","year":"2018","journal-title":"Oncotarget"},{"issue":"1","key":"10.1016\/j.lungcan.2026.109471_b0225","doi-asserted-by":"crossref","first-page":"9054","DOI":"10.1038\/s41598-022-13236-8","article-title":"Cellular engagement and interaction in the tumor microenvironment predict non-response to PD-1\/PD-L1 inhibitors in metastatic non-small cell lung cancer","volume":"12","author":"Qin","year":"2022","journal-title":"Sci. Rep."},{"issue":"7","key":"10.1016\/j.lungcan.2026.109471_b0230","doi-asserted-by":"crossref","DOI":"10.1001\/jamanetworkopen.2019.6879","article-title":"Association of survival and immune-related biomarkers with immunotherapy in patients with non-small cell lung cancer: a meta-analysis and individual patient-level analysis","volume":"2","author":"Yu","year":"2019","journal-title":"JAMA Netw. Open"},{"issue":"19","key":"10.1016\/j.lungcan.2026.109471_b0235","article-title":"Prognostic role of KRAS G12C mutation in non-small cell lung cancer. A systematic review and meta-analysis","volume":"13","author":"Wankhede","year":"2023","journal-title":"Diagnostics (Basel)"},{"issue":"7","key":"10.1016\/j.lungcan.2026.109471_b0240","doi-asserted-by":"crossref","first-page":"8373","DOI":"10.18632\/oncotarget.7080","article-title":"KRAS mutation is a weak, but valid predictor for poor prognosis and treatment outcomes in NSCLC: a meta-analysis of 41 studies","volume":"7","author":"Pan","year":"2016","journal-title":"Oncotarget"},{"issue":"1","key":"10.1016\/j.lungcan.2026.109471_b0245","doi-asserted-by":"crossref","first-page":"352","DOI":"10.1186\/s12885-023-10778-6","article-title":"Overall survival in patients with advanced non-small cell lung cancer with KRAS G12C mutation with or without STK11 and\/or KEAP1 mutations in a real-world setting","volume":"23","author":"Julian","year":"2023","journal-title":"BMC Cancer"},{"issue":"5","key":"10.1016\/j.lungcan.2026.109471_b0250","doi-asserted-by":"crossref","DOI":"10.3390\/cancers14051321","article-title":"Direct targeting KRAS mutation in non-small cell lung cancer: focus on resistance","volume":"14","author":"Reita","year":"2022","journal-title":"Cancers (Basel)"},{"key":"10.1016\/j.lungcan.2026.109471_b0255","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.lungcan.2021.05.026","article-title":"A retrospective observational study of the natural history of advanced non-small-cell lung cancer in patients with KRAS p.G12C mutated or wild-type disease","volume":"159","author":"Spira","year":"2021","journal-title":"Lung Cancer"},{"issue":"1","key":"10.1016\/j.lungcan.2026.109471_b0260","article-title":"Brief report: not created equal: survival differences by KRAS mutation subtype in NSCLC treated with immunotherapy","volume":"6","author":"Sun","year":"2025","journal-title":"JTO Clin Res Rep"},{"key":"10.1016\/j.lungcan.2026.109471_b0265","unstructured":"Referenced with permission from the NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines\u00ae) for Guideline Name 8.2025. \u00a9 National Comprehensive Cancer Network, Inc. 2025. All rights reserved. Accessed [October 11, 2025]. To view the most recent and complete version of the guideline, go online to NCCN.org."},{"key":"10.1016\/j.lungcan.2026.109471_b0275","doi-asserted-by":"crossref","DOI":"10.3389\/fphar.2022.920165","article-title":"Efficacy and safety of combined immunotherapy and antiangiogenesis with or without chemotherapy for advanced non-small-cell lung cancer: a systematic review and pooled analysis from 23 prospective studies","volume":"13","author":"Gao","year":"2022","journal-title":"Front. Pharmacol."},{"key":"10.1016\/j.lungcan.2026.109471_b0280","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2025.1635056","article-title":"Do age and performance status matter? A systematic review and network meta-analysis of immunotherapy studies in untreated advanced\/metastatic non-oncogene addicted NSCLC","volume":"16","author":"Siciliano","year":"2025","journal-title":"Front Immunol"},{"issue":"8","key":"10.1016\/j.lungcan.2026.109471_b0285","doi-asserted-by":"crossref","DOI":"10.3390\/ijms20081915","article-title":"Beyond PD-L1 markers for lung cancer immunotherapy","volume":"20","author":"Wojas-Krawczyk","year":"2019","journal-title":"Int. J. Mol. Sci."},{"issue":"2","key":"10.1016\/j.lungcan.2026.109471_b0290","doi-asserted-by":"crossref","DOI":"10.3390\/cancers13020277","article-title":"The multiple potential biomarkers for predicting immunotherapy response-finding the needle in the haystack","volume":"13","author":"Adam","year":"2021","journal-title":"Cancers (Basel)"},{"issue":"1","key":"10.1016\/j.lungcan.2026.109471_b0295","doi-asserted-by":"crossref","first-page":"10255","DOI":"10.1038\/s41598-017-10925-7","article-title":"PD-L1 expression in lung cancer and its correlation with driver mutations: a meta-analysis","volume":"7","author":"Zhang","year":"2017","journal-title":"Sci. Rep."},{"issue":"2","key":"10.1016\/j.lungcan.2026.109471_b0300","doi-asserted-by":"crossref","DOI":"10.1136\/jitc-2021-003027","article-title":"Clinical efficacy of atezolizumab plus bevacizumab and chemotherapy in KRAS-mutated non-small cell lung cancer with STK11, KEAP1, or TP53 comutations: subgroup results from the phase III IMpower150 trial","volume":"10","author":"West","year":"2022","journal-title":"J. Immunother. Cancer"},{"issue":"2","key":"10.1016\/j.lungcan.2026.109471_b0305","doi-asserted-by":"crossref","first-page":"113","DOI":"10.1056\/NEJMoa1713137","article-title":"Osimertinib in untreated EGFR-mutated advanced non-small-cell lung cancer","volume":"378","author":"Soria","year":"2018","journal-title":"N. Engl. J. Med."},{"issue":"1","key":"10.1016\/j.lungcan.2026.109471_b0310","doi-asserted-by":"crossref","DOI":"10.1080\/15384047.2024.2441499","article-title":"First-line treatments for KRAS-mutant non-small cell lung cancer: current state and future perspectives","volume":"26","author":"He","year":"2025","journal-title":"Cancer Biol. Ther."},{"issue":"5","key":"10.1016\/j.lungcan.2026.109471_b0315","doi-asserted-by":"crossref","first-page":"527","DOI":"10.1007\/s40265-024-02030-7","article-title":"Targeting KRAS(G12C) in non-small-cell lung cancer: current standards and developments","volume":"84","author":"Torres-Jimenez","year":"2024","journal-title":"Drugs"},{"issue":"2","key":"10.1016\/j.lungcan.2026.109471_b0320","doi-asserted-by":"crossref","first-page":"e115","DOI":"10.3747\/co.24.3355","article-title":"Factors influencing treatment selection and survival in advanced lung cancer","volume":"24","author":"Tabchi","year":"2017","journal-title":"Curr. Oncol."},{"issue":"2","key":"10.1016\/j.lungcan.2026.109471_b0325","doi-asserted-by":"crossref","DOI":"10.1136\/jitc-2023-008189","article-title":"Four-year clinical update and treatment switching-adjusted outcomes with first-line nivolumab plus ipilimumab with chemotherapy for metastatic non-small cell lung cancer in the CheckMate 9LA randomized trial","volume":"12","author":"Carbone","year":"2024","journal-title":"J. Immunother. Cancer"},{"issue":"19","key":"10.1016\/j.lungcan.2026.109471_b0330","doi-asserted-by":"crossref","DOI":"10.3390\/cancers13194846","article-title":"Nationwide survival benefit after implementation of first-line immunotherapy for patients with advanced NSCLC-real world efficacy","volume":"13","author":"Mouritzen","year":"2021","journal-title":"Cancers (Basel)"},{"issue":"7","key":"10.1016\/j.lungcan.2026.109471_b0335","doi-asserted-by":"crossref","first-page":"e443","DOI":"10.1016\/j.cllc.2022.06.007","article-title":"Evaluating real world mutational differences between Hispanics and Asians in NSCLC at a large academic institution in Los Angeles","volume":"23","author":"Hsu","year":"2022","journal-title":"Clin. Lung Cancer"},{"issue":"4","key":"10.1016\/j.lungcan.2026.109471_b0340","doi-asserted-by":"crossref","first-page":"487","DOI":"10.1016\/j.jtho.2022.11.030","article-title":"Tobacco smoking-related mutational signatures in classifying smoking-associated and nonsmoking-associated NSCLC","volume":"18","author":"Ernst","year":"2023","journal-title":"J. Thorac. Oncol."},{"key":"10.1016\/j.lungcan.2026.109471_b0345","doi-asserted-by":"crossref","DOI":"10.1177\/17588359241231260","article-title":"Geographic differences in lung cancer: focus on carcinogens, genetic predisposition, and molecular epidemiology","volume":"16","author":"Laguna","year":"2024","journal-title":"Ther. Adv. Med. Oncol."}],"container-title":["Lung Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0169500226005325?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0169500226005325?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,6,15]],"date-time":"2026-06-15T12:39:20Z","timestamp":1781527160000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0169500226005325"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,7]]},"references-count":68,"alternative-id":["S0169500226005325"],"URL":"https:\/\/doi.org\/10.1016\/j.lungcan.2026.109471","relation":{},"ISSN":["0169-5002"],"issn-type":[{"value":"0169-5002","type":"print"}],"subject":[],"published":{"date-parts":[[2026,7]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"First-line treatment patterns and real-world outcomes in patients with advanced KRAS-mutated non-small cell lung cancer with high unmet need","name":"articletitle","label":"Article Title"},{"value":"Lung Cancer","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.lungcan.2026.109471","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 The Authors. Published by Elsevier B.V.","name":"copyright","label":"Copyright"}],"article-number":"109471"}}